Company Overview

Company Overview

Larimar Therapeutics, based in the Philadelphia area, is committed to discovering and developing treatments for complex rare diseases, with an initial focus on Friedreich’s ataxia. Its proprietary protein replacement therapy platform is intended to deliver missing proteins inside the machinery of cells to treat devastating rare diseases that currently have ineffective or no treatments available.

Our Platform

Proprietary intracellular delivery platform intended to deliver proteins and other molecules inside cells.

Our Platform >

Friedreich’s ataxia Clinical Trial

Currently in a Phase 1 trial, CTI-1601, is intended to deliver human frataxin to patients with Friedreich’s ataxia.

Clinical Trial >